Dimethyl Sulfoxide
Apexbio Technology LLC Wortmannin 19545-26-7 10mM (in 1mL DMSO)
Wortmannin is a selective inhibitor targeting phosphatidylinositol-3-kinase (PI3K) with reported IC50 of approximately 1 9 nM It inhibits PI3K through an ATP-noncompetitive binding mechanism interacting directly with the catalytic region Additionally wortmannin functions as a noncompetitive inhibitor of myosin light chain kinase (MLCK) with an IC50 around 1 9 M thus decreasing myosin light chain phosphorylation and associated smooth muscle contraction In biomedical research wortmannin is commonly employed to dissect the PI3K signaling pathway evaluate smooth muscle contractility and explore therapeutic potentials related to vascular dilation and inflammation modulation
Apexbio Technology LLC Fruquintinib(HMPL-013) 1194506-26-7 10mM (in 1mL DMSO)
Fruquintinib (HMPL-013 CAS 1194506-26-7) is a small molecule inhibitor targeting VEGFR family receptor tyrosine kinases (VEGFR1 VEGFR2 and VEGFR3) It demonstrates potent inhibitory activity with reported IC50 values of approximately 33 nM (VEGFR1) 35 nM (VEGFR2) and 0 5 nM (VEGFR3) Kinase selectivity screening indicates limited off-target effects against other kinases such as RET FGFR-1 and c-kit In preclinical tumor xenograft studies (e g gastric cancer BGC-823 model) significant tumor growth suppression ( 80%) was achieved at sustained therapeutic exposure Fruquintinib is currently under clinical investigation for cancer treatment based on its selective VEGFR pathway inhibition
Apexbio Technology LLC Veliparib dihydrochloride 912445-05-7 10mM (in 1mL DMSO)
Veliparib dihydrochloride (CAS 912445-05-7) is a selective inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 enzymes responsible for DNA repair processes frequently upregulated in various cancers Veliparib inhibits PARP1 and PARP2 with K(i) values of 5 2 and 2 9 nmol/L respectively In colon cancer cell lines (HCT-116 HT-29) veliparib enhances DNA damage and induces G2/M arrest when combined with SN38 or oxaliplatin In preclinical murine melanoma (B16F10) breast cancer (MX-1) and colon cancer (HCT-116) xenografts combination therapy with DNA-damaging agents shows improved antitumor effects